(Q34423519)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24907378%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

title

IL-2: the first effective immunotherapy for human cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24907378%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

Steven A Rosenberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24907378%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

language of work or name

English

0 references

publication date

1 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24907378%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

published in

Journal of Immunology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24907378%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

192

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24907378%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24907378%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

5451-5458

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24907378%20AND%20SRC:MED&resulttype=core&format=json

Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.

20 March 2020

cites work

1 reference

12 December 2020

In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

1 reference

12 December 2020

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

1 reference

12 December 2020

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

12 December 2020

Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma

1 reference

12 December 2020

Long term growth in vitro of human T cell blasts with maintenance of specificity and function

1 reference

12 December 2020

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

1 reference

12 December 2020

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

1 reference

12 December 2020

The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma

1 reference

12 December 2020

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study

1 reference

12 December 2020

Cancer regression in patients after transfer of genetically engineered lymphocytes

1 reference

12 December 2020

Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer

1 reference

12 December 2020

Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies

1 reference

12 December 2020

Passive Immunotherapy of Cancer in Animals and Man

1 reference

12 December 2020

Monoclonal cytolytic T-cell lines

1 reference

12 December 2020

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

1 reference

12 December 2020

Lymphokine-activated killer cells: a new approach to immunotherapy of cancer

1 reference

12 December 2020

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

12 December 2020

Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

1 reference

12 December 2020

Long term culture of tumour-specific cytotoxic T cells

1 reference

12 December 2020

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

12 December 2020

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

1 reference

12 December 2020

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

12 December 2020

Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells

1 reference

12 December 2020

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

1 reference

12 December 2020

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

1 reference

12 December 2020

Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials

1 reference

12 December 2020

In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens

1 reference

12 December 2020

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

1 reference

12 December 2020

Adoptive immunotherapy for cancer: building on success

1 reference

12 December 2020

Cancer immunotherapy: moving beyond current vaccines

1 reference

12 December 2020

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

1 reference

12 December 2020

In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma

1 reference

12 December 2020

Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2

1 reference

12 December 2020

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

12 December 2020

A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy

1 reference

12 December 2020

Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes

1 reference

12 December 2020

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

1 reference

12 December 2020

In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.

1 reference

12 December 2020

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

12 December 2020

Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma

1 reference

12 December 2020

Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer

1 reference

12 December 2020

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

12 December 2020

In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells

1 reference

12 December 2020

In vitro growth of murine T cells. VI. Accelerated skin graft rejection caused by adoptively transferred cells expanded in T cell growth factor

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

1 reference

12 December 2020

Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2

1 reference

12 December 2020

In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin-free T cell growth factor (TCGF) and an analysis of its activity

1 reference

12 December 2020

Comparison of in vivo cell distribution following either intraperitoneal or intravenous injection of lymphoid cells

1 reference

12 December 2020

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

12 December 2020

Purification and partial sequence analysis of human T-cell growth factor

1 reference

12 December 2020

Molecular cloning of human interleukin 2 cDNA and its expression inE. coli

1 reference

12 December 2020

Long-term culture of human antigen-specific cytotoxic T-cell lines

1 reference

12 December 2020

Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

1 reference

12 December 2020

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.

1 reference

12 December 2020

Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma

1 reference

12 December 2020

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

1 reference

12 December 2020

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

12 December 2020

Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2

1 reference

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

12 December 2020

In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.

1 reference

12 December 2020

In vitro growth of murine T cells. IV. Use of T-cell growth factor to clone lymphoid cells

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

1 reference

12 December 2020

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

12 December 2020

In vitro growth of murine T cells. III. Method for separation of T cell growth factor (TCGF) from concanavalin A and biological activity of the resulting TCGF

1 reference

12 December 2020

Cancer genome landscapes

1 reference

12 December 2020

Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy

1 reference

12 December 2020

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 reference

12 December 2020

Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells

1 reference

12 December 2020

An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy

1 reference

12 December 2020

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

12 December 2020

Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.

1 reference

12 December 2020

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

1 reference

12 December 2020

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

1 reference

12 December 2020

The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors

1 reference

12 December 2020

In vitro growth of murine T cells. II. Growth of in vitro sensitized cells cytotoxic for alloantigens

1 reference

12 December 2020

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

12 December 2020

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts

1 reference

12 December 2020

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

1 reference

12 December 2020

Identifiers

DOI

10.4049/JIMMUNOL.1490019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24907378%20AND%20SRC:MED&resulttype=core&format=json

release_2z7ulma6hvbprmbeuxxyramp44

20 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2z7ulma6hvbprmbeuxxyramp44

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24907378%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

PubMed publication ID

24907378

1 reference